Author: slightbourne@noblecapitalmarkets.com

Bitcoin Rebounds Above $71K as Crypto Markets Shake Off Geopolitical Shock

Posted on by slightbourne@noblecapitalmarkets.com

Bitcoin staged a sharp rebound this week, briefly climbing above $71,000 as digital assets recovered from a global risk-off selloff tied to escalating conflict in the Middle East. The move highlights the continued volatility—and resilience—of the world’s largest cryptocurrency as investors reassess its role in uncertain macro conditions.

The price of Bitcoin surged as much as 5.7% during Wednesday trading, reaching roughly $71,890, its highest level in nearly a month. While the rally cooled slightly during early New York trading, Bitcoin remained firmly above $71,000. Ether followed with a similar move, climbing more than 6% to around $2,090, while most major cryptocurrencies traded higher.

The rebound follows several turbulent sessions across global markets. Over the weekend, geopolitical tensions escalated after U.S. and Israeli forces carried out strikes in Iran, triggering widespread volatility across equities, commodities, and digital assets. Bitcoin dropped sharply during the initial reaction, briefly falling to about $63,000 before buyers stepped back in.

A key factor supporting the rebound has been continued demand for spot Bitcoin exchange-traded funds in the United States. According to Bloomberg data, spot Bitcoin ETFs attracted more than $680 million in combined inflows over Monday and Tuesday, suggesting institutional investors remain active participants in the asset class despite recent market stress.

For small- and middle-market investors, ETF flows remain an important signal of broader market sentiment. These investment vehicles have become one of the primary bridges connecting traditional capital markets with the crypto ecosystem. When inflows accelerate, they can amplify price momentum by channeling new institutional capital into Bitcoin.

Bitcoin’s recent performance has also revived the long-running debate over whether cryptocurrencies can function as a safe-haven asset during geopolitical crises. Crypto advocates have long positioned Bitcoin as “digital gold,” but that narrative has been inconsistent in practice.

In recent months, gold surged to record highs while Bitcoin struggled through a prolonged correction. Even after this week’s rally, Bitcoin remains roughly 40% below its October peak following a multi-month downturn.

However, over the past several days the relationship has temporarily flipped. While gold prices briefly dipped earlier this week amid shifting inflation expectations in bond markets, Bitcoin rallied nearly 9% from last Friday levels.

Some analysts believe traders may be positioning for potential monetary easing if global economic conditions deteriorate amid prolonged geopolitical conflict. Digital assets, which tend to benefit from liquidity-driven market environments, often attract speculative inflows during periods when investors anticipate easier financial conditions.

Despite the rebound, the broader backdrop remains fragile. Military exchanges between Israel and Iran have entered their fifth day, and global financial markets remain highly sensitive to additional developments. Equity volatility and shifting interest rate expectations continue to influence institutional positioning across asset classes—including crypto.

For now, Bitcoin’s recovery above $70,000 underscores the asset’s ability to rebound quickly after sharp drawdowns. But the same volatility that drives rapid rallies also leaves the market vulnerable to sudden reversals.

For investors, the latest price action serves as a reminder that Bitcoin increasingly trades within the broader macro ecosystem—responding not only to crypto-specific catalysts but also to geopolitical risk, liquidity conditions, and institutional capital flows.

As the digital asset market matures, these cross-market dynamics are likely to play an even larger role in shaping Bitcoin’s price trajectory.

Greenwich LifeSciences, Inc. (GLSI) – FLAMIMGO-01 Trial Screening Rate Now Higher Than Expected

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, March 04, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Patient Screening Is Ahead Of Expectations. Greenwich LifeSciences reported a large increase in the rate of patient screening in the FLAMINGO-01 Phase 3 trial. The rate increased to about 200 patients per quarter, reaching an annual rate of over 800 per year, compared with the previous rate of 600 patients per year. The reflects an increased number of patients at existing sites as well as opening of additional sites in Europe. We see this increase in same-site and additional site screening as a positive sign for the trial.

Additional Data Release Coming Soon. In late February, Greenwich announced that two abstracts were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held April 17-22, 2026. The AACR plans to publish the abstract titles on March 17, followed by the full abstracts on April 17. The full posters will be published on the date of presentation at the conference.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Star Equity Holdings, Inc. (STRR) – A Mini Berkshire In the Making

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, March 04, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiation. We are initiating equity research coverage on Star Equity Holdings, Inc. with an Outperform rating and $16 price target. A diversified holding company, Star is seeking to replicate the Berkshire Hathaway playbook in the micro-cap space. The Company currently operates through 3 operating divisions, growing both organically and through acquisitions, and a fourth investment division, which makes strategic investments in public companies.

Multi-Pronged Growth Strategy. Management is pursuing a multi-pronged growth strategy. First and foremost is organic growth in the existing operating verticals. The second strategy is growth via acquisitions, with both the public and private arenas targeted. Lastly, through the Investments division, Star will make targeted investments in select microcaps. These could be potential acquisition targets or just strategic investments in companies that management has determined are trading at a discount to fair value.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Superior Group of Companies (SGC) – Efficiency Initiatives Drive Earnings Growth

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, March 04, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid finish to the year. The company reported Q4 revenue of $146.6 million and adj. EBITDA of $9.9 million, both of which were largely in line with our estimates of $145.4 million and $9.1 million, respectively. Furthermore, revenue increased 1% year over year and 6% sequentially, reflecting the expected back-end weighted cadence, while strong cost controls drove meaningful profitability improvement. 

Cost discipline drives earnings growth. SG&A declined $1.4 million year over year, and EBITDA increased 19% to $8.6 million, resulting in a 90 basis point improvement in EBITDA margin. EPS of $0.23, nearly doubled from the comparable prior-year quarter.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Power Metallic Mines Inc. (PNPNF) – Drilling Expands Lion Mineralization and Identifies High-Grade Gold Zone

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, March 04, 2026

Power Metallic is a Canadian exploration company focused on advancing the Nisk Project Area (Nisk–Lion–Tiger)—a high–grade Copper–PGE, Nickel, gold and silver system—toward Canada’s next polymetallic mine. On 1 February 2021, Power Metallic (then Chilean Metals) secured an option to earn up to 80% of the Nisk project from Critical Elements Lithium Corp. (TSX–V: CRE). Following the June 2025 purchase of 313 adjoining claims (~167 km²) from Li–FT Power, the Company now controls ~212.86 km² and roughly 50 km of prospective basin margins. Power Metallic is expanding mineralization at the Nisk and Lion discovery zones, evaluating the Tiger target, and exploring the enlarged land package through successive drill programs. Beyond the Nisk Project Area, Power Metallic indirectly has an interest in significant land packages in British Columbia and Chile, by its 50% share ownership position in Chilean Metals Inc., which were spun out from Power Metallic via a plan of arrangement on February 3, 2025. It also owns 100% of Power Metallic Arabia which owns 100% interest in the Jabul Baudan exploration license in The Kingdon of Saudi Arabia’s JabalSaid Belt. The property encompasses over 200 square kilometres in an area recognized for its high prospectivity for copper gold and zinc mineralization. The region is known for its massive volcanic sulfide (VMS) deposits, including the world-class Jabal Sayid mine and the promising Umm and Damad deposit.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Expansion of Lion mineralization. Recent drilling at Lion East and Lion West resulted in a newly identified shallow eastward plunging structural trend that controls high grade copper mineralization and extends the Lion system beyond its previously defined limits. Step-out drilling expanded mineralization both east and west, and the emerging structural model may vector toward a larger nickel copper source at depth, enhancing the project’s long-term potential.

Encouraging results at Lion West. Drilling intersected massive nickel-bearing sulphide within the UM zone, indicating the presence of a deeper nickel-palladium-copper system much like mineralization observed at Tiger. Follow-up drilling is underway to better define the geometry and relationship to the Lion geological stratigraphy.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Anthropic-Pentagon Clash Puts AI Ethics — and Hype — Under the Small-Cap Spotlight

Posted on by slightbourne@noblecapitalmarkets.com

The escalating dispute between Anthropic and the U.S. Department of Defense is quickly becoming more than a policy debate. It’s a flashpoint for how artificial intelligence companies — public and private — balance rapid commercialization with ethical guardrails.

And for small-cap investors, the episode is a reminder that regulatory and reputational risk can reshape capital flows overnight.

Last week, the Trump administration ordered government agencies to stop using Anthropic’s chatbot, Claude, and labeled the company a supply chain risk after CEO Dario Amodei declined to loosen safeguards preventing use of its models in autonomous weapons and mass surveillance. Anthropic has indicated it plans to challenge the decision once formal notice is received.

The market reaction has been swift.

According to Sensor Tower, Claude surged past ChatGPT in U.S. app downloads over the weekend. Meanwhile, OpenAI faced consumer backlash after announcing a Pentagon agreement to replace Anthropic in classified environments. ChatGPT’s one-star reviews spiked sharply in Apple’s app store following the news, prompting CEO Sam Altman to acknowledge the rollout was mishandled.

The episode highlights a widening divide in AI strategy: aggressive government integration versus caution around high-stakes use cases.

But beneath the headlines lies a more structural issue — readiness.

Missy Cummings, director of the robotics and automation center at George Mason University and a former Navy fighter pilot, recently argued that generative AI systems should not control or guide weapons due to persistent reliability issues. Large language models, she noted, are prone to “hallucinations” and remain unsuitable for environments where errors could cost lives.

Anthropic’s leadership has echoed similar concerns, stating that frontier AI systems are not yet reliable enough to power fully autonomous weapons.

For investors, particularly in small- and mid-cap technology names, the debate underscores a key theme for 2026: execution risk tied to real-world deployment.

Government contracts can provide validation and revenue visibility. But they also introduce political exposure, regulatory scrutiny, and headline volatility. Private AI leaders like Anthropic and OpenAI may dominate public discourse, but publicly traded players — from Palantir (PLTR), which has longstanding defense ties, to Apple (AAPL), whose app ecosystem reflects consumer sentiment in real time — are often the ones absorbing market swings.

The situation also revives questions about what some critics have called the industry’s “hype cycle.” Years of bold claims around AI autonomy and decision-making capabilities helped accelerate defense adoption. Now, as policymakers confront the technology’s limitations, that enthusiasm is meeting institutional caution.

For small-cap investors, this dynamic matters.

Emerging AI infrastructure providers, cybersecurity firms, data analytics companies, and niche software developers frequently market defense or government pathways as long-term growth drivers. Yet this episode illustrates that capital access and contract durability can hinge on shifting ethical standards and public perception — not just technological performance.

It also reinforces a broader capital markets takeaway: reputational capital is financial capital.

Anthropic’s consumer download surge suggests ethical positioning can resonate with users. But legal challenges and lost government business could weigh on enterprise relationships. Conversely, OpenAI’s Pentagon alignment may strengthen federal revenue prospects while pressuring brand perception.

As AI migrates from consumer chatbots into mission-critical systems, readiness — technical, regulatory, and ethical — will increasingly define winners and laggards.

For small-cap investors, the lesson is clear: in emerging technologies, policy risk is no longer a side variable. It’s central to valuation.

Markets in Shock: What History Says About Oil, Gold, and Stocks After Global Conflict

Posted on by slightbourne@noblecapitalmarkets.com

The US and Israeli strikes on Iran have rattled global markets, triggering sharp swings in oil, gold, and equities. Brent crude surged, gold climbed, and the S&P 500 whipsawed as investors grappled with the possibility of a prolonged conflict.

Whenever geopolitical tensions erupt, the first market reaction is often dramatic. Energy prices spike on supply fears. Gold rallies as investors seek safety. Stocks wobble amid uncertainty.

But history suggests that the first move is rarely the lasting one.

A review of past geopolitical shocks — including Iraq’s invasion of Kuwait in 1990, the Sept. 11 attacks, the 2003 Iraq War, US intervention in Libya, and Russia’s invasion of Ukraine — shows a consistent pattern. Markets tend to react sharply in the opening days, only to moderate or reverse course within weeks.

Consider the 12-day conflict between Israel and Iran in June 2025. When hostilities began on June 13, oil and gold jumped immediately while stocks fell.

Brent crude rose roughly 7% in the first trading session following the outbreak of fighting. Yet 30 trading days later, oil prices were slightly below where they had started.

Gold followed a similar trajectory. An initial pop of about 1.5% gave way to a modest decline over the next month.

Equities moved in the opposite direction. The S&P 500 fell just over 1% on the first day of trading after the conflict began but was up nearly 6% a month later.

The lesson: initial fear-driven moves do not necessarily define the medium-term trend.

The same dynamic appeared after other major events. Gold surged nearly 7% in the first trading session after the Sept. 11, 2001 attacks, reflecting a rush into safe-haven assets. But over the subsequent 30 trading days, gains were far more moderate.

Oil’s reaction to Russia’s invasion of Ukraine in 2022 was even more dramatic. Prices spiked more than 30% in the early days of the conflict amid fears of supply disruptions. Yet a month later, oil’s net gain had narrowed significantly.

Across multiple episodes, the direction of prices after the first day matched the direction one month later only slightly more than half the time. In other words, a sharp spike — or drop — offers limited predictive power.

There is, however, at least one important exception.

When Iraq invaded Kuwait in August 1990, oil prices jumped more than 11% on the first day and continued climbing, rising nearly 57% over the following month. Stocks also continued their downward trajectory, with the S&P 500 falling more than 10% over 30 trading days.

Even in that case, however, markets eventually recovered after allied forces expelled Iraqi troops from Kuwait.

The current conflict may ultimately chart its own course. The scale of military action, potential energy supply disruptions, and broader geopolitical consequences all remain fluid. Analysts have cautioned that it is simply too early to project where prices will settle in the weeks ahead.

Still, history offers a measured perspective. Markets often overshoot in moments of crisis, pricing in worst-case scenarios before recalibrating as new information emerges.

For investors, that pattern underscores a familiar reality: volatility may dominate the headlines in the first days of a global shock, but longer-term outcomes are rarely determined by the opening move alone.

Gyre Therapeutics, Inc (GYRE) – Cullgen Acquisition Adds New Platform To Build Long-Term Pipeline

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, March 03, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Gyre To Acquire Cullgen.  Gyre Therapeutics announced the acquisiton of Cullgen, a privately-held company developing targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies. The all-stock transaction valued Cullgen at approximately $300 million. We believe this acquisition adds a novel technology platform to the mid-term to long-term product pipeline.

The Cullgen Acquisition Transforms Gyre. Cullgen was private company founded in 2018. It has been developing its proprietary technology platform, uSMITE (ubiquitin-mediated small molecule-induced target elimination), to create targeted protein degrading drugs and antibody conjugates. These drugs are in development to treat pain, cancer, inflammation, autoimmune diseases, and neurodegenerative diseases.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – Funds to Pursue Growth

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, March 03, 2026

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Raise. Kratos raised a net $1.35 billion through the sale of 16,285,571 KTOS shares at $84/sh, including the Underwriters exercising the 30-day allotment in full. The offering closed on  March 2, 2026. Noble Capital participated in the raise.

Uses. The net funds will be used to continue to make important capital expenditures to scale operations and meet the growing demands of  The Department of War and National Security customers with respect to existing programs, recently awarded contracts and new opportunities, (ii) to continue to invest in new product, system and software product development, (iii) to strengthen the Company’s balance sheet to allow the Company to be responsive to anticipated contract awards from the large, strategic pipeline of opportunities, (iv) to fund the recent acquisition of Nomad, pending acquisition of Orbit, and select future strategic M&A opportunities, and (v) for general corporate purposes.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Strait of Hormuz in Focus as U.S.-Iran War Sends Oil Markets Soaring

Posted on by slightbourne@noblecapitalmarkets.com

Oil markets have swung sharply higher since the outbreak of war between the United States and Iran, with traders rapidly repricing geopolitical risk into crude benchmarks. U.S. crude rose more than 5% Monday after surging as much as 12% intraday, while Brent climbed above $77 per barrel before easing from session highs. The moves reflect mounting concern that the conflict could trigger sustained supply disruptions in one of the world’s most strategically vital energy corridors.

At the center of the market’s anxiety is the Strait of Hormuz, the narrow waterway linking the Persian Gulf to global markets. Shipping analysts report that tanker traffic through the Strait has effectively stalled as operators reassess security risks. In 2025, more than 14 million barrels per day—roughly one-third of the world’s seaborne crude exports—passed through this chokepoint. A prolonged disruption would have immediate consequences for refiners and importers across Asia, Europe, and North America.

Iran itself produces approximately 3.3 million barrels per day, ranking as OPEC’s fourth-largest oil producer. Beyond its own output, however, its geographic position gives it indirect leverage over exports from Saudi Arabia, Iraq, Kuwait, and the United Arab Emirates. The conflict introduces overlapping supply risks: potential declines in Iranian production due to instability or infrastructure damage, and constraints on maritime transit that could temporarily restrict exports from multiple Gulf producers. Even the perception of restricted flows has been enough to trigger aggressive buying in crude futures and energy-linked equities.

Major banks have begun outlining upside price scenarios if the disruption persists. Some analysts suggest Brent could approach $100 per barrel under an extended supply squeeze, while more severe regional escalation could drive prices materially higher. For now, markets are oscillating between risk premium expansion and cautious optimism that diplomatic channels could reopen. President Donald Trump stated that U.S. combat operations will continue until objectives are met, while also indicating openness to talks. Iranian officials have publicly rejected negotiations, adding to uncertainty over the conflict’s trajectory.

The implications extend well beyond the energy sector. A sustained rally in crude would complicate global inflation dynamics at a time when central banks have been attempting to stabilize price pressures. Higher oil prices feed directly into transportation, manufacturing, and consumer goods costs, potentially delaying interest rate normalization. Equity markets, particularly rate-sensitive and consumer-facing sectors, could experience renewed volatility if energy-driven inflation reaccelerates.

For small- and mid-cap companies, the effects are uneven. Domestic exploration and production firms may benefit from improved pricing and stronger cash flow if elevated crude levels persist. Oilfield services providers could also see renewed capital spending from producers seeking to capitalize on higher margins. Conversely, airlines, logistics operators, chemicals manufacturers, and other fuel-intensive businesses face margin compression if input costs rise faster than pricing power allows. Emerging market equities in energy-importing nations may also encounter currency and trade balance pressures.

The broader theme resurfacing in 2026 is the fragility embedded in global supply chains. While U.S. shale growth and diversified sourcing have added resilience over the past decade, the Strait of Hormuz remains irreplaceable in the near term. Even with strategic petroleum reserves and spare capacity assumptions, a chokepoint freeze underscores how quickly geopolitical flashpoints can ripple through commodity markets and financial assets.

Oil is once again functioning as a real-time geopolitical barometer. Until tanker traffic resumes at scale or a clearer diplomatic path emerges, volatility is likely to remain elevated. Investors across asset classes will be watching crude not only as an energy benchmark, but as a signal of broader macroeconomic risk.

RadNet Buys Gleamer, Building a Global Radiology AI Powerhouse

Posted on by slightbourne@noblecapitalmarkets.com

RadNet (NASDAQ: RDNT) is making a decisive move in healthcare AI. The Los Angeles-based outpatient imaging leader announced it has acquired Paris-based Gleamer SAS, integrating the business into its DeepHealth digital subsidiary. The all-cash deal, valued at up to €230 million including a post-closing milestone, positions DeepHealth as what the company describes as the largest provider of radiology clinical AI solutions worldwide.

For investors, the transaction underscores how artificial intelligence is shifting from pilot projects to scaled deployment across diagnostic imaging.

Gleamer brings more than 700 customer contracts across 44 countries and a cloud-first AI portfolio spanning musculoskeletal, breast, lung and neurologic applications. Its solutions include FDA-cleared and CE-marked products designed to support radiologists in screening, detection and workflow prioritization.

DeepHealth, RadNet’s digital health arm, already offers AI-enabled imaging tools across breast, chest, neuro, prostate and thyroid care. Combined, the companies report more than 2,700 customer contracts globally, a portfolio of 26 FDA-cleared and 22 CE-marked devices, and coverage across MR, CT, X-ray, mammography and ultrasound.

That breadth matters in a market where imaging volumes continue to rise while radiologist shortages persist worldwide.

RadNet CEO Dr. Howard Berger framed the deal around workflow automation—particularly in high-volume modalities like X-ray, ultrasound and mammography—where AI-enabled prioritization and draft reporting may help maintain access and efficiency.

Gleamer has operated under a SaaS model, generating annual recurring revenue (ARR) from subscription-based contracts. The company reported a compound annual ARR growth rate exceeding 90% from 2022 through 2025 and expects to reach approximately $30 million in ARR in 2026.

RadNet indicated that, on a combined basis, DeepHealth and Gleamer anticipate ARR approaching or exceeding $140 million by the end of 2026. ARR is a non-GAAP metric representing contracted recurring revenue and excludes one-time implementation and hardware sales.

For public market investors, recurring revenue visibility is increasingly central to valuation in health tech and AI-enabled platforms. The addition of Gleamer enhances DeepHealth’s cloud-native revenue base and expands its European footprint at a time when regulatory-cleared AI tools are gaining broader institutional adoption.

Beyond external sales, RadNet intends to deploy Gleamer’s AI capabilities across its own imaging network, which spans multiple U.S. states and performs millions of exams annually.

X-ray accounts for nearly 25% of RadNet’s imaging volume. The company expects AI-enabled triage and draft reporting tools to support productivity gains and workflow standardization, with deployment targeted by the third quarter of 2026.

Management has emphasized that benefits could include improved resource utilization and cost efficiencies. As with all integration efforts, realization of these outcomes depends on execution and adoption across clinical teams.

The acquisition arrives amid accelerating consolidation in healthcare AI, as imaging platforms seek both modality breadth and geographic reach. Hospitals and outpatient providers are increasingly evaluating enterprise-wide AI solutions rather than single-use tools.

By combining Gleamer’s automated reporting capabilities—already deployed in Europe—with DeepHealth’s imaging informatics platform, RadNet is aiming to deliver an integrated operating system approach across the radiology workflow.

Investors should view the transaction as part of a broader capital allocation strategy: pairing RadNet’s stable outpatient imaging cash flows with scalable digital health assets that carry higher growth profiles.

As AI moves from experimental deployments to embedded clinical infrastructure, scale, regulatory clearance and recurring revenue models are becoming competitive differentiators. RadNet’s latest acquisition suggests the next phase of radiology AI will be defined less by innovation alone—and more by integration at enterprise scale.

Titan International (TWI) – Reports Fourth Quarter Results

Posted on by slightbourne@noblecapitalmarkets.com


Monday, March 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Titan ended 2025 with another positive quarter as fourth quarter revenue, gross margin, and adjusted EBITDA exceeded fourth quarter 2024 results. These results are ahead of management’s revenue guidance and also better than adjusted EBITDA expectations. The EMC segment was the standout performer, with revenue growth of 21% and gross margin expansion of 3.4 percentage points.

4Q25 Results. Revenue grew 7.0% to $410.4 million. Ex foreign exchange, the Ag segment was flat, EMC up nicely, and Consumer down modestly. Adjusted EBITDA came in at $11 million, up 18% y-o-y. Due to non-cash valuation allowances, Titan recorded a GAAP net loss of $56 million in the quarter, compared to net income of $1.3 million in 4Q24. Adjusted net loss was $17.4 million, or $0.27/sh, compared to net income of $5.8 million, or $0.09/sh, in 4Q24.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – Ateganosine Moves Forward With A Pivotal Year Ahead

Posted on by slightbourne@noblecapitalmarkets.com


Monday, March 02, 2026

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Building On Success In 2025, Ateganosine Continues Moving Forward. MAIA has been conducting the Phase 2 THIO-101 trial, testing ateganosine (also known as THIO) in combination with cemiplimab, a checkpoint inhibitor. The trial is now in its third stage after the data showed meaningful improvements in median survival, overall response rates, and disease control rate. Separately, a Phase 3 trial has begun. Based on the reported results, we believe both trials have a high probability of success and could lead to FDA approvals.

Phase 2 THIO-101 Could Support Early Approval. The THIO-101 trial was designed with three stages. Part A confirmed safety and tolerabity, while Part B tested three doses to determine the optimal dosing regimen. In December 2025, the Part C Expansion/Registration stage began. This is an open-label arm designed to determine the Overall Response Rate (ORR). Positive data could lead to an application for Early Approval from the FDA.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.